Fanconi Anemia: Causes, Symptoms, Diagnosis, and Treatment

What is Fanconi Anemia?

Fanconi anemia, also known as Fanconi pancytopenia, is a rare and serious inherited disorder that affects approximately 1 in every 136,000 live births worldwide. Despite being classified under the broader category of anemias, it is important to understand that Fanconi anemia is far more than a simple blood disorder. It is a complex, multi-system genetic disease that profoundly affects bone marrow function, causes a wide range of congenital malformations, and carries a dramatically elevated risk of developing certain cancers, particularly leukemia.

To understand what makes this disease distinctive, it is helpful to break down the two key terms in its name:

• Anemia: A reduction in the number of circulating red blood cells (or their hemoglobin content), leading to decreased oxygen delivery to the body’s tissues.
• Aplastic: Referring to aplastic anemia, a condition in which the bone marrow’s blood-forming (hematopoietic) stem cells are damaged or absent. This results in the failure to produce adequate numbers of all blood cell types.

However, the clinical picture of Fanconi anemia is significantly more extensive and grave than aplastic anemia alone. In this condition, the bone marrow (the spongy tissue inside bones responsible for producing white blood cells, red blood cells, and platelets from precursor cells called promyelocytes) fails to generate sufficient numbers of all three major blood cell lineages. This global deficiency of blood cells in the peripheral circulation is called pancytopenia (from the Greek: pan = all, cyto = cell, penia = deficiency).

The disease is transmitted in an autosomal recessive pattern, meaning that an individual must inherit a defective copy of the causative gene from both parents in order to manifest the disease. When only one defective copy is inherited, the individual becomes a healthy carrier and does not develop the condition, but can pass the gene on to their children.

Although the disease does not show a strong sex-linked predilection in most cases, males appear to be at somewhat higher risk for certain manifestations and complications.

Fanconi anemia typically presents in childhood and follows a progressive course. Its clinical manifestations extend well beyond hematological abnormalities and include:

• Skin changes: Abnormal pigmentation of the skin, including café-au-lait spots (light brown patches), hyperpigmentation, or areas of hypopigmentation (loss of skin color, similar to vitiligo).
• Ophthalmological problems: Including microphthalmia (abnormally small eyes) and nystagmus (involuntary eye movements).
• Hearing difficulties: Including sensorineural hearing loss.
• Cardiac defects: Various structural heart abnormalities.
• Urogenital abnormalities: Less common, but including kidney malformations and reproductive organ defects.

Perhaps most significantly, individuals with Fanconi anemia have a dramatically increased predisposition to develop congenital malformations. These are structural abnormalities present from birth, affecting the skeleton, skin, urogenital system, and central nervous system. They also face a markedly elevated lifetime risk of developing leukemia and other solid tumors.

The life expectancy of individuals with Fanconi anemia is significantly reduced compared to the general population. The average survival has historically been reported at around 20 to 30 years, though this has improved in recent years with advances in treatment, particularly stem cell transplantation. In the most severe cases, the disease can be fatal within the first 5 to 9 years of life.

Diagnosis relies on a combination of clinical evaluation, family history assessment, and specific laboratory testing. The most important test is chromosomal fragility testing using diepoxybutane (DEB) or mitomycin C (MMC), which reveals the characteristic chromosomal instability t hat defines the disease.

Treatment primarily involves bone marrow or stem cell transplantation, ideally from a compatible donor. Additional supportive and disease-modifying therapies are available and continue to evolve as research progresses.

---

Causes and Transmission

The Genetic Basis of Fanconi Anemia

Fanconi anemia is an inherited genetic disease caused by mutations in genes involved in a critical cellular process: detecting and repairing certain types of DNA damage, particularly interstrand crosslinks (ICLs). These lesions covalently join the two strands of the DNA double helix, blocking DNA replication and transcription. Without functional DNA repair, cells accumulate genomic damage and are unable to maintain normal function or divide properly.

To date, researchers have identified 22 genes, designated FANCA through FANCW (with some letters skipped), whose mutations can cause Fanconi anemia. These genes encode proteins that form part of a complex molecular pathway known as the Fanconi anemia (FA) DNA damage response pathway. When this pathway is disrupted due to mutations in any of these FANC genes, cells become hypersensitive to agents that cause DNA crosslinks (such as certain chemotherapy drugs and environmental toxins), and chromosomes become abnormally fragile.

The distribution of mutations across the known FA genes is not uniform. The most commonly affected genes are:

• FANCA: Accounts for approximately 60–70% of all Fanconi anemia cases, making it by far the most frequently mutated gene.
• FANCC: Accounts for approximately 10–15% of cases.
• FANCG: Accounts for approximately 8–10% of cases.
• Mutations in all other FANC genes together account for the remaining, relatively rare cases.

The underlying cellular abnormality in all cases is chromosomal fragility, which refers to an abnormal tendency for chromosomes to break, rearrange, and develop structural abnormalities. This issue is especially common during cell division, or mitosis. This genomic instability is the hallmark of Fanconi anemia at the cellular level and explains both the bone marrow failure (as blood cell precursors cannot divide normally) and the elevated cancer risk (as accumulated DNA damage promotes malignant transformation).

Inheritance Patterns

Fanconi anemia is inherited in an autosomal recessive manner in the vast majority of cases. The key principles are:

• Both copies of the gene must be mutated for the disease to manifest. Since most FANC genes are located on non-sex chromosomes (autosomes), both males and females are equally affected.
• Carriers (heterozygotes), individuals who inherit one mutated and one normal copy of a FANC gene, are phenotypically healthy and do not develop Fanconi anemia. However, they carry the mutated gene and can pass it to their children.
• When both parents are carriers, each pregnancy carries:
  • A 25% probability of the child inheriting two mutated copies and developing Fanconi anemia.
  • A 50% probability of the child being a healthy carrier.
  • A 25% probability of the child inheriting two normal copies and being completely unaffected.
• A child of a carrier parent and a healthy (non-carrier) parent has a 50% probability of being a carrier and a 50% probability of being unaffected. They cannot develop the disease from this pairing.

X-Linked Form

In approximately 1% of Fanconi anemia cases, the disease is caused by a mutation in the FANCB gene, which is located on the X chromosome (one of the two sex chromosomes, alongside the Y chromosome). This results in an X-linked inheritance pattern with the following important differences:

• Because males have only one X chromosome (XY), a single mutated copy of FANCB is sufficient to cause the full disease in males.
• Because females have two X chromosomes (XX), they must inherit two mutated copies of FANCB to develop the disease; if they have only one mutated copy, they are typically healthy carriers (though very rare skewed X-inactivation scenarios can cause mild phenotypes).
• In X-linked Fanconi anemia, affected males are born to carrier mothers who usually do not show signs of the disease themselves.

This X-linked form disproportionately affects males and is caused exclusively by FANCB mutations, which are among the most severe FA gene mutations, often resulting in a very serious clinical phenotype that may include pronounced VACTERL-like malformations (vertebral, cardiac, tracheo-esophageal, renal, and limb defects).

Why Is Chromosomal Fragility So Damaging?

The fundamental consequence of FANC gene mutations is the failure to repair DNA interstrand crosslinks. When cells attempt to replicate their DNA before dividing (during the S phase of the cell cycle), these unrepaired crosslinks act as insurmountable roadblocks. The cell may attempt alternative, error-prone repair mechanisms, leading to:

• Chromosomal breaks and rearrangements, visible under the microscope after exposure to crosslinking agents (the basis of the DEB test used for diagnosis).
• Accumulation of mutations in critical genes, increasing the probability of malignant transformation over time.
• Cell death (apoptosis) of bone marrow precursors, causing the progressive depletion of blood cell production that characterizes the aplastic anemia component of the disease.

Understanding this molecular mechanism is crucial for developing targeted therapies and has been an area of intense research activity in recent years.

---

Symptoms

The clinical presentation of Fanconi anemia is extraordinarily diverse and complex. It varies substantially from one individual to another, even within the same family or with the same genetic mutation. Some individuals present with severe, life-threatening manifestations at birth, while others may reach adolescence or even adulthood before the disease becomes apparent. This clinical variability makes diagnosis challenging and underscores the importance of specialist evaluation.

The main categories of symptoms and clinical findings include:

1. Physical Malformations, Anomalies, and Structural Defects

A substantial proportion of individuals with Fanconi anemia, estimated at approximately 60 to 75 percent, are born with one or more congenital physical malformations. These can affect virtually any organ system and include:

Craniofacial Abnormalities

• Microcephaly: Abnormally small head circumference, which may be associated with cognitive difficulties.
• Micrognathia: Underdevelopment of the jaw (mandible), which can cause feeding difficulties in infancy and dental problems.
• Facial asymmetry

Ophthalmological Abnormalities

• Microphthalmia: Abnormally small eyes.
• Nystagmus: Involuntary, repetitive eye movements that impair visual acuity.
• Structural eye defects including epicanthal folds, ptosis (drooping eyelid), and strabismus (crossed eyes).

Musculoskeletal Abnormalities

• Thumb abnormalities: Absent, hypoplastic (underdeveloped), or duplicated thumbs are among the most characteristic physical features of Fanconi anemia and are present in the majority of cases with skeletal involvement.
• Radial ray defects: Abnormalities of the radius bone in the forearm, which may be accompanied by thumb abnormalities.
• Short stature: Significantly reduced height compared to age-matched peers, which may be due to growth hormone deficiency, nutritional deficits, or intrinsic skeletal abnormalities.
• Abnormalities of other digits and limbs.
• Scoliosis and other spinal defects.

Auditory Abnormalities

• Sensorineural hearing loss (deafness): Caused by abnormalities of the inner ear or auditory nerve. This can range from mild to severe and significantly impacts development and quality of life.
• Structural ear abnormalities.

Cardiac Defects

• Various congenital heart defects have been described, including ventricular septal defect (VSD), patent ductus arteriosus (PDA), and other structural anomalies.
• Cardiac complications contribute significantly to morbidity and require specialized cardiological follow-up.

Renal and Urogenital Abnormalities

• Kidney malformations: Including horseshoe kidney (fusion of the two kidneys), unilateral renal agenesis (absence of one kidney), ectopic kidney (abnormally positioned kidney), and duplicated ureters.
• Genital abnormalities: Including hypospadias (abnormal urethral opening) in males, and uterine or vaginal anomalies in females.
• Hypogonadism: Impaired function of the gonads (testes in males, ovaries in females), leading to hormonal deficiencies and fertility problems.

Gastrointestinal Abnormalities

• Structural defects of the esophagus (tracheoesophageal fistula, esophageal atresia).
• Ano-rectal malformations including imperforate anus.
• These gastrointestinal defects may require surgical correction in the neonatal period.

Skin and Pigmentation Abnormalities

• Café-au-lait spots: Flat, light-brown patches on the skin that are a classic feature of Fanconi anemia.
• Generalized hyperpigmentation: Areas of darkened skin, particularly in skin folds and sun-exposed areas.
• Vitiligo-like hypopigmentation: Patches of lighter skin due to loss of melanocytes.
• These skin changes are often one of the earliest observable findings that prompt further investigation.

2. Developmental and Cognitive Deficits

• Short stature (as noted above), which may reflect growth hormone deficiency in some patients.
• Anorexia and feeding difficulties, which can compromise nutrition and further impair growth.
• Intellectual disability: Ranging from mild to moderate cognitive impairment. Not all patients are affected, but learning difficulties and neurodevelopmental delays are common.
• Learning disorders and attention difficulties: Even in patients without frank intellectual disability, academic challenges are frequently reported.

3. Bone Marrow Failure (Pancytopenia)

This is the most clinically dangerous component of Fanconi anemia and the primary driver of morbidity and mortality. Progressive failure of the bone marrow to produce adequate numbers of all three major blood cell lineages leads to:

• Anemia (red blood cell deficiency): Causes fatigue, weakness, pallor, shortness of breath, and poor exercise tolerance.
• Neutropenia (white blood cell deficiency): Dramatically increases susceptibility to bacterial, viral, and fungal infections, which can be life-threatening.
• Thrombocytopenia (platelet deficiency): Leads to easy bruising, petechiae (tiny red dots under the skin from small bleeds), prolonged bleeding from minor cuts, and risk of serious or fatal hemorrhage.

The onset of bone marrow failure is typically observed between 3 and 12 years of age and tends to worsen progressively over time. It is the most common cause of death in patients with Fanconi anemia who do not undergo stem cell transplantation.

4. Associated Malignancies

Fanconi anemia is associated with a strikingly elevated lifetime risk of developing certain cancers, which represents a second major cause of death in this population:

• Acute myeloid leukemia (AML): The most common hematological malignancy in Fanconi anemia, with an estimated cumulative risk of approximately 10–15% by age 40.
• Myelodysplastic syndromes (MDS): Pre-leukemic conditions characterized by dysplastic (abnormal) blood cell production that can evolve into frank leukemia.
• Solid tumors: Patients with Fanconi anemia have a markedly elevated risk of developing squamous cell carcinomas of the head and neck (particularly oral cavity, pharynx, and esophagus), anogenital carcinomas (vulvar, vaginal, and cervical cancers in women; penile and anal cancers in men), and liver tumors (hepatocellular carcinoma, particularly in patients treated with androgens).

5. Symptoms That Emerge Over Time

As patients with Fanconi anemia reach adolescence and adulthood, additional manifestations related to endocrine and reproductive function become apparent:

• Fertility problems and incomplete development of sex organs: Both males and females with Fanconi anemia commonly experience reduced or absent fertility due to gonadal failure or malformation.
• In females:
  • Delayed menarche: The first menstrual period is often significantly delayed compared to peers.
  • Menstrual irregularities: Irregular, infrequent, or absent menstrual cycles.
  • Premature menopause: Ovarian failure occurring well before the expected age of natural menopause.
  • Recurrent miscarriages: Those women who do achieve pregnancy face an elevated risk of pregnancy loss.
• In males: Hypogonadism, reduced testosterone production, and azoospermia (absence of sperm) are common.

---

Complications

Beyond the core clinical features described above, Fanconi anemia is associated with a range of serious complications that can further compromise patient health and significantly impact quality of life and survival.

Life-Threatening Infections

Severe neutropenia (low white blood cell count) resulting from bone marrow failure leaves patients with Fanconi anemia highly vulnerable to a wide spectrum of infections. Unlike healthy individuals who can rapidly mount an immune response to bacteria, viruses, and fungi, patients with Fanconi anemia may develop overwhelming, rapidly progressive infections that can be fatal within hours if not promptly recognized and treated.

Particularly dangerous infections include:

• Bacterial sepsis: Bloodstream infections caused by common bacteria (such as Staphylococcus aureus, Streptococcus pneumoniae, and gram-negative bacteria like Escherichia coli or Pseudomonas aeruginosa) that a healthy immune system would normally contain.
• Invasive fungal infections: Including aspergillosis and candidiasis, which are particularly difficult to treat in immunocompromised patients.
• Viral infections: Reactivation of latent viruses (such as cytomegalovirus [CMV] and Epstein-Barr virus [EBV]) can cause serious illness in immunosuppressed patients.

Any febrile illness in a patient with Fanconi anemia must be treated as a medical emergency requiring immediate evaluation and empiric treatment.

Hemorrhage

Severe thrombocytopenia (platelet deficiency) creates a significant risk of uncontrolled bleeding. While minor manifestations like easy bruising and nosebleeds are common, the most dangerous scenarios involve internal hemorrhage. In particular, intracranial bleeding, which is bleeding into the brain, can be fatal or cause permanent neurological damage. Gastrointestinal hemorrhage and bleeding into other vital structures are also serious possibilities.

Malignant Transformation

As described in the symptoms section, the chromosomal instability inherent to Fanconi anemia creates a profoundly elevated cancer risk throughout the patient’s lifetime. The development of acute myeloid leukemia, myelodysplastic syndrome, or solid tumors (particularly head and neck squamous cell carcinomas) represents a major cause of morbidity and mortality. These cancers often arise at younger ages than in the general population, may be more aggressive in their behavior, and present additional treatment challenges given the underlying fragility of the patient’s DNA repair machinery (which affects tolerance to chemotherapy and radiation).

End-Organ Damage from Recurrent Cytopenias

Chronic and recurrent deficiencies of all blood cell types impose cumulative stress on multiple organ systems:

• Cardiac strain from chronic anemia (the heart must work harder to compensate for reduced oxygen-carrying capacity).
• Growth impairment from nutritional deficits compounded by chronic illness.
• Neurological complications in the setting of intracranial hemorrhage or severe anemia.

Complications of Treatment

It is important to recognize that some complications in Fanconi anemia are related not just to the disease itself, but to its treatment:

• Androgen therapy (used to stimulate blood cell production) is associated with an increased risk of hepatic complications, including liver tumors (hepatocellular adenomas and carcinomas), and may potentially worsen the risk of certain other malignancies.
• Stem cell transplantation carries risks including graft rejection, graft-versus-host disease (GVHD), and transplant-related infections and organ toxicities.

---

Diagnosis

The Diagnostic Challenge

Due to its rarity and the extraordinary variability of its clinical presentation, the diagnosis of Fanconi anemia can be extremely challenging. Patients may present at widely different ages and with vastly different constellations of symptoms. A high index of clinical suspicion is therefore essential, particularly in children who present with bone marrow failure, characteristic physical malformations, or unexpectedly severe reactions to chemotherapy or radiation therapy. These treatments exploit the same DNA crosslinking mechanisms that are defective in FA cells.

Clinical Evaluation and Family History

The diagnostic process begins with a thorough clinical assessment:

• Physical examination: A detailed head-to-toe examination is performed to identify characteristic physical malformations. These may include thumb and radial abnormalities, café-au-lait spots, microcephaly, short stature, ear and eye anomalies, as well as cardiac and renal abnormalities.
• Family history: A comprehensive family history should be obtained to identify known cases of Fanconi anemia, bone marrow failure, early-onset cancer, or congenital malformations in relatives. Consanguinity (related parents) significantly increases the probability of autosomal recessive conditions.

The Gold Standard: Chromosomal Fragility Testing (DEB Test)

The definitive diagnostic test for Fanconi anemia is the chromosomal fragility test, most commonly performed using diepoxybutane (DEB) or mitomycin C (MMC) as the crosslinking agent. This test exploits the fundamental molecular defect in Fanconi anemia:

• A blood sample (or other cell sample) is obtained from the patient.
• Cells are cultured and exposed to DEB or MMC.
• Chromosomal preparations are examined under a microscope.
• In patients with Fanconi anemia, the cells show a dramatically increased frequency of chromosomal breaks, rearrangements, and radial figures (complex chromosome configurations involving multiple chromosomes).
• In normal individuals, chromosomal breakage after DEB/MMC exposure is minimal.

This test is highly sensitive and specific for Fanconi anemia and should be performed in any patient with unexplained bone marrow failure or a clinical picture suggestive of the disease.

Additional Laboratory Investigations

Alongside the DEB test, a range of additional investigations are typically ordered:

• Complete blood count (CBC): Reveals pancytopenia, which means low red blood cells, white blood cells, and platelets. The pattern and severity of cytopenias provides important information about the degree of bone marrow failure.
• Reticulocyte count: Measures the number of immature red blood cells (reticulocytes) in the blood. A low reticulocyte count confirms that the bone marrow is failing to adequately compensate for red blood cell loss.
• Bone marrow biopsy and aspirate: A sample of bone marrow tissue is obtained (usually from the hip bone under local anesthesia) and examined microscopically. In Fanconi anemia, the bone marrow typically shows hypocellularity (reduced numbers of blood-forming cells) and may reveal dysplastic (abnormal) cells or early malignant transformation.
• Hemoglobin F (fetal hemoglobin) level: Often elevated in Fanconi anemia, as the bone marrow partially reverts to producing fetal-type hemoglobin as a compensatory mechanism.
• Hormone levels: Assessment of growth hormone, thyroid function, sex hormones, and insulin-like growth factor 1 (IGF-1) to evaluate endocrine complications.
• Renal and hepatic function tests: To assess the degree of organ involvement.
• Imaging studies: Including renal ultrasound, echocardiography, and skeletal X-rays to characterize structural abnormalities.

Genetic Testing

Once the diagnosis is confirmed by chromosomal fragility testing, molecular genetic testing is performed to identify the specific causative mutation(s) and the FANC gene involved. This is important for:

• Genetic counseling of the patient and family members.
• Carrier testing of siblings and other family members.
• Prenatal diagnosis in future pregnancies.
• Identifying compatible stem cell donors (particularly for sibling donors).
• Research and participation in clinical trials.

Multidisciplinary Team Approach

Given the multi-organ nature of Fanconi anemia, diagnosis and ongoing management requires a multidisciplinary team of specialists working in coordination:

• Hematologist: Central to managing bone marrow failure and malignancy risk.
• Geneticist/Clinical Geneticist: For molecular diagnosis, genetic counseling, and family studies.
• Pediatrician: For overall child health management and developmental monitoring.
• Cardiologist: For evaluation and management of cardiac defects.
• Nephrologist: For renal monitoring and management.
• Orthopedic surgeon: For skeletal malformations.
• Ophthalmologist: For vision assessment and monitoring.
• Audiologist/ENT specialist: For hearing assessment and management.
• Endocrinologist: For hormonal abnormalities and growth issues.
• Gynecologist/Obstetrician: For reproductive counseling and prenatal care.
• Oncologist: For cancer surveillance and treatment if malignancy develops.

Timing of Diagnosis

The timing of diagnosis varies depending on the presenting features:

• If the baby is born with characteristic physical malformations (e.g., thumb abnormalities, café-au-lait spots), appropriate diagnostic tests can and should be performed immediately in the neonatal period.
• Signs of bone marrow failure typically emerge between 3 and 12 years of age, at which point hematological investigations reveal pancytopenia and prompt further workup.
• In milder cases, the diagnosis may not be made until adolescence or adulthood, sometimes only when a patient has an unexpectedly severe reaction to chemotherapy or when a family member is diagnosed.

Prenatal Diagnosis

When there is a known family history of Fanconi anemia (e.g., a previously affected sibling), prenatal diagnosis is available to determine whether the fetus has inherited the disease:

• Chorionic villus sampling (CVS): A small sample of placental tissue (chorionic villi) is obtained between 10 and 12 weeks of gestation. The sample can be subjected to DEB testing or molecular genetic analysis to detect Fanconi anemia.
• Amniocentesis: A sample of amniotic fluid (containing fetal cells) is obtained after 15 weeks of gestation and similarly analyzed.

These procedures carry a small risk of pregnancy complications and should be performed at experienced centers with appropriate genetic counseling before and after testing.

Preimplantation genetic diagnosis (PGD) in the context of in vitro fertilization (IVF) is also an option for couples who wish to avoid the risk of an affected pregnancy, allowing selection of unaffected embryos before implantation. This approach can also identify embryos that are HLA-matched to an existing affected sibling, enabling the birth of a donor sibling whose cord blood stem cells can be used for transplantation.

---

Treatment

Principles of Management

The management of Fanconi anemia is complex, highly individualized, and must be adapted to the patient’s age, genotype, clinical severity, and specific complications. Because the disease is progressive and affects multiple organ systems, treatment must be continuous and long-term, with regular monitoring through serial laboratory investigations, imaging, and specialist assessments.

There is currently no treatment that addresses the underlying genetic defect in the majority of patients, though gene therapy holds promise for the future. Current treatment strategies aim to:

• Correct or compensate for bone marrow failure.
• Manage specific organ malformations and complications.
• Prevent and treat infections.
• Detect and treat malignancies early.
• Improve and maintain quality of life.

1. Hematopoietic Stem Cell Transplantation (HSCT)

Bone marrow and hematopoietic stem cell transplantation is the most effective treatment currently available for the bone marrow failure component of Fanconi anemia and, when successful, represents a cure for the hematological aspects of the disease (though not for the non-hematological manifestations or the cancer risk from solid tumors).

In HSCT, the patient’s defective bone marrow is destroyed using a conditioning regimen (chemotherapy, and sometimes low-dose radiation) and replaced with healthy stem cells from a donor. Key aspects include:

• Donor selection: The b est outcomes are achieved with a matched sibling donor (MSD). This refers to a brother or sister who is genetically compatible (HLA-matched) and does not have Fanconi anemia. When a sibling is available and compatible, survival rates with HSCT can exceed 85% at 5 years.
• Unrelated donors: When no matched sibling is available, transplantation using a matched unrelated donor (MUD) or alternative donors (such as haploidentical family members or cord blood) is increasingly successful, though outcomes remain somewhat less favorable than with matched sibling donors.
• Conditioning regimens: Patients with Fanconi anemia are exquisitely sensitive to DNA-damaging agents (by definition), so standard conditioning regimens used in other settings are far too toxic. Reduced-intensity conditioning regimens, which use lower doses of chemotherapy (typically fludarabine-based) with or without low-dose radiation, have been developed specifically for FA patients. These regimens have substantially improved transplant safety.
• Stem cell sources: Stem cells can be harvested from:
  • Bone marrow (the traditional source)
  • Peripheral blood (stem cells mobilized into the bloodstream by growth factors and collected by apheresis)
  • Umbilical cord blood (collected at birth from the umbilical cord of a compatible newborn sibling)
• Autologous transplantation: In some experimental settings, the patient’s own stem cells are harvested, corrected ex vivo using gene therapy techniques, and reinfused. This approach avoids graft rejection and GVHD but is still largely investigational.

The main risks of HSCT include:

• Graft failure: The transplanted cells fail to engraft and the patient’s own bone marrow does not recover.
• Graft-versus-host disease (GVHD): The donor immune cells recognize the patient’s tissues as foreign and attack them. GVHD can affect the skin, liver, gut, lungs, and other organs, and can be life-threatening.
• Infections: During the period of immunosuppression following transplantation, patients are at high risk for severe infections.
• Transplant-related organ toxicity

It is important to note that while HSCT corrects bone marrow failure and hematological malignancy risk, it does not eliminate the elevated risk of solid tumors (particularly head and neck cancers) associated with Fanconi anemia. Life-long cancer surveillance remains essential even after successful transplantation.

2. Androgen Therapy

Androgens, male sex hormones such as oxymetholone or danazol, have been a long-standing treatment for Fanconi anemia. They help stimulate blood cell production in the bone marrow: specifically, erythropoiesis (red blood cell formation) and thrombopoiesis (platelet formation). They act by increasing the production of erythropoietin and by directly stimulating hematopoietic precursors, thereby temporarily improving red blood cell and platelet counts.

However, androgen therapy has significant limitations and risks:

• It is not a cure: It does not address the underlying genetic defect or halt the progression of bone marrow failure. The response tends to diminish over time, and most patients eventually require transplantation despite androgen therapy.
• Side effects: Include liver toxicity, such as peliosis hepatis, adenomas, and rarely hepatocellular carcinoma. They may also cause virilization, which involves masculinizing effects like increased body hair, voice deepening, and clitoral enlargement in females. Additionally, these substances can accelerate growth while causing premature closure of bone growth plates, potentially reducing final adult height. Importantly, they increase the risk of liver tumors.
• Monitoring: Patients on androgen therapy require regular liver function tests and liver imaging to detect hepatic complications early.

Despite these limitations, androgen therapy remains a useful temporizing measure in patients awaiting transplantation or those who are not candidates for it, buying time by maintaining blood counts at safer levels.

3. Hematopoietic Growth Factors

Hematopoietic growth factors, biological agents that stimulate the bone marrow to produce specific blood cell types, can be used in selected patients to temporarily improve blood counts.

• Granulocyte colony-stimulating factor (G-CSF): Stimulates the production of neutrophils (white blood cells), reducing the risk of bacterial infections.
• Erythropoietin (EPO): Stimulates red blood cell production, reducing anemia.

These agents are generally used as supportive measures rather than definitive treatments.

4. Blood Transfusions

Red blood cell transfusions are given to treat symptomatic anemia, offering immediate relief from fatigue, shortness of breath, and other related symptoms. Platelet transfusions are given to control active bleeding or to reduce hemorrhage risk when platelet counts fall to dangerously low levels.

Regular transfusions carry the risk of iron overload (as the body cannot effectively eliminate excess iron from transfused blood), potentially damaging the liver, heart, and endocrine organs. Iron chelation therapy (using agents such as deferoxamine or deferasirox) may be required to prevent or treat iron overload in patients receiving frequent transfusions.

5. Infection Prevention and Treatment

Given the severe immunocompromise associated with neutropenia and post-transplant immunosuppression, infection management is a critical component of care:

• Prophylactic antibiotics and antifungals: To reduce the risk of bacterial and fungal infections, particularly during periods of severe neutropenia.
• Antiviral prophylaxis: Particularly important post-transplant to prevent reactivation of herpes viruses (CMV, EBV, herpes simplex, varicella-zoster).
• Immunization: Patients should receive all recommended vaccinations, with particular attention to vaccines against encapsulated bacteria (pneumococcus, meningococcus, Haemophilus influenzae type b), influenza, and hepatitis B. Live vaccines must be used with caution in immunocompromised patients.
• Prompt treatment of infections: Any febrile episode requires urgent evaluation and empiric broad-spectrum antibiotic therapy pending identification of the causative organism.

6. Surgical Correction of Malformations

Many patients with Fanconi anemia benefit from surgical correction of congenital malformations. The nature and timing of surgical intervention depends on the specific defect and its clinical impact:

• Cardiac defects may require surgical repair in infancy.
• Gastrointestinal malformations (e.g., tracheoesophageal fistula, imperforate anus) typically require emergency surgical intervention in the neonatal period.
• Skeletal malformations (e.g., radial aplasia, thumb abnormalities) may be surgically addressed in early childhood.
• Urogenital defects may require urological or gynecological surgery.

Surgical planning must take into account the patient’s hematological status and the increased anesthetic and healing risks associated with anemia and thrombocytopenia.

7. Gene Therapy: An Emerging Curative Option

Gene therapy represents perhaps the most promising frontier in the treatment of Fanconi anemia. The conceptual approach involves:

• Harvesting the patient’s own hematopoietic stem cells.
• Correcting the genetic defect ex vivo: Insert a functional copy of the mutated FANC gene into the stem cells using a viral vector, most commonly a lentiviral vector.
• Reinfusing the corrected stem cells into the patient, where they engraft and begin producing genetically normal blood cells.

This approach has the potential to provide a cure for bone marrow failure without the risks of graft rejection or GVHD. This is because the patient’s own cells are used, avoiding the complications associated with allogeneic (donor) transplantation.

Several clinical trials are currently underway, and early-phase results have been encouraging, particularly for patients with FANCA mutations (the most common genetic subtype). The gene therapy program developed at the Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) in Spain has produced notable clinical data demonstrating engraftment of corrected cells and hematological improvement in some patients.

However, gene therapy for Fanconi anemia remains experimental and is currently available only within the context of clinical trials at specialized centers. Challenges include:

• Harvesting sufficient numbers of stem cells from patients with severely damaged bone marrow.
• Ensuring long-term engraftment and sustained correction.
• Preventing insertional mutagenesis, which is the risk that the viral vector integrates into an oncogene and could potentially cause cancer. Modern lentiviral vectors, however, are designed to minimize this risk.

As research advances, gene therapy is expected to become an increasingly important curative option for patients with Fanconi anemia, potentially replacing or complementing allogeneic transplantation in many cases.

8. Cancer Surveillance and Treatment

Given the dramatically elevated risk of leukemia and solid tumors, regular cancer surveillance is an essential component of long-term care for all patients with Fanconi anemia:

• Annual bone marrow examination (aspirate and biopsy) to detect early signs of myelodysplastic syndrome or leukemic transformation.
• Regular head and neck examination (including oral cavity, pharynx, and larynx) should be performed at least annually from adolescence onward, as there is a high risk of squamous cell carcinoma.
• Gynecological screening (PAP smear, HPV vaccination, vulvar and cervical examination) for female patients.
• Liver ultrasound (particularly for patients on androgen therapy) to detect hepatic tumors.

When malignancy does develop, treatment must be carefully adapted to the patient’s underlying fragility, as standard chemotherapy and radiation regimens can be extremely toxic in Fanconi anemia patients. Specialist oncological input is essential.

9. Supportive and Symptomatic Care

In addition to the disease-specific treatments above, comprehensive supportive care is an integral part of management:

• Nutritional support: To address anorexia, growth failure, and the increased metabolic demands of chronic illness.
• Psychological support and mental health care: Living with a serious chronic genetic disease has profound psychological impacts on patients and their families. Access to psychologists, social workers, and peer support groups is important.
• Educational support: For children with learning difficulties or intellectual disability, tailored educational plans and specialized support are essential.
• Reproductive counseling: For patients who reach reproductive age, discussion of fertility options, pregnancy risks, and genetic counseling is important.
• Endocrine management: Including growth hormone therapy for growth hormone deficiency, and sex hormone replacement for hypogonadism.
• Regular audiological assessment and hearing aids for patients with hearing loss.
• Ophthalmological care for vision abnormalities.

---

Prevention

Because Fanconi anemia is a genetic disorder caused by inherited mutations in specific genes, it cannot be prevented in the traditional sense. In other words, no lifestyle modifications or environmental interventions can stop a child from inheriting the defective genes if both parents are carriers.

However, several measures can help reduce the risk of an affected pregnancy or enable early identification and treatment:

Genetic Counseling

When there is a known family history of Fanconi anemia (e.g., an affected child, a known carrier parent, or a positive family history in multiple relatives), the couple should be offered comprehensive genetic counseling by a clinical geneticist. Genetic counseling provides:

• Accurate assessment of inheritance risk based on each partner’s carrier status and the specific genetic mutations involved.
• Information about available reproductive options, including prenatal diagnosis, preimplantation genetic diagnosis (PGD), use of donor gametes, or adoption.
• Emotional support and help in making informed reproductive decisions.

Carrier Testing

Both members of a couple with a family history of Fanconi anemia should undergo carrier testing (molecular genetic testing for the specific FANC gene mutations known in their family). Broader carrier screening panels, which test for Fanconi anemia along with other recessive genetic disorders, are also increasingly available and can identify carrier status even in the absence of a known family history.

Prenatal Diagnosis

As described in the Diagnosis section, chorionic villus sampling (CVS) or amniocentesis can be used to determine whether a fetus has inherited Fanconi anemia, allowing parents to make informed decisions about the pregnancy.

Preimplantation Genetic Testing (PGT)

For couples who wish to avoid the risk of an affected pregnancy and choose to undergo IVF, preimplantation genetic testing for monogenic disease (PGT-M) allows the selection of unaffected embryos for transfer. This can include testing for both Fanconi anemia status and HLA compatibility with an affected sibling, if applicable.

Newborn Screening

While Fanconi anemia is not yet included in universal newborn screening programs in most countries, it may be identified through targeted testing if characteristic malformations are noted at birth. Expanding newborn screening programs to include Fanconi anemia could enable earlier diagnosis and intervention, particularly for patients who do not present with obvious malformations at birth.

General Health Optimization

For individuals already diagnosed with Fanconi anemia, or for known carriers at risk of having affected children, general health measures like avoiding smoking, excessive alcohol, and unnecessary exposure to carcinogens may help reduce the elevated cancer risk. However, these steps cannot eliminate the risk entirely.

---

Conclusions

Fanconi anemia is a rare but serious multi-system genetic disorder that requires lifelong, multidisciplinary care. Its combination of bone marrow failure, congenital malformations, and dramatically elevated cancer risk creates unique and challenging management needs. The prognosis depends heavily on how quickly the disease is diagnosed and whether patients can access specialized care. Unfortunately, these factors often work against patients because the disease is both rare and complex.

Advances in reduced-intensity conditioning regimens for stem cell transplantation have substantially improved outcomes for patients with bone marrow failure. Emerging gene therapy approaches hold promise for a future in which a genetic cure is available without the risks of allogeneic transplantation. And increasing recognition of the importance of lifelong cancer surveillance is helping to detect and treat malignancies earlier, when outcomes are more favorable.

Despite these advances, Fanconi anemia remains a profoundly challenging condition, and continued investment in research, patient support, and clinical expertise is essential to improving the lives of those affected.

---

Sources and Bibliography

• Mehta, P. A., & Tolar, J. (2018). Fanconi Anemia. In GeneReviews®. National Center for Biotechnology Information (NCBI). https://europepmc.org/article/nbk/nbk1401
• Alter, B. P. (2014). “Fanconi anemia and the development of leukemia”. Best Practice & Research Clinical Haematology, 27(3-4), 214–221. https://doi.org/10.1016/j.beha.2014.10.002
• Kutler, D. I., Singh, B., Satagopan, J., et al. (2003). “A 20-year perspective on the International Fanconi Anemia Registry (IFAR)”. Blood, 101(4), 1249–1256. https://doi.org/10.1182/blood-2002-07-2170
• Fanconi Anemia Research Fund (FARF). Fanconi Anemia: Guidelines for Diagnosis and Management (5th edition). https://www.fanconi.org/
• Leblanc, T., & Gluckman, E. (2022). “Fanconi anemia: Current management”. Hematology/Oncology Clinics of North America, 36(4), 821–840.
• Bogliolo, M., & Surrallés, J. (2015). “Fanconi anemia: A model disease for studies on human genetics and advanced therapeutics”. Current Opinion in Genetics & Development, 33, 32–40. https://doi.org/10.1016/j.gde.2015.07.002
• Río, P., Navarro, S., & Bueren, J. A. (2018). “Advances in gene therapy for Fanconi anemia”. Human Gene Therapy, 29(10), 1114–1123. https://doi.org/10.1089/hum.2018.124
• National Organization for Rare Disorders (NORD). “Fanconi Anemia”. https://rarediseases.org/rare-diseases/fanconi-anemia/
• European Fanconi Anemia Research Fund (EFARF). https://www.fanconi.eu/
• Dufour, C., et al. (2020). “Treatment of Fanconi anemia: The state of the art”. Pediatric Reports, 12(s1), 8751. https://doi.org/10.4081/pr.2020.8751
• National Institutes of Health (NIH), National Heart, Lung, and Blood Institute. “Aplastic Anemia”. https://www.nhlbi.nih.gov/health/aplastic-anemia
• Rosenberg, P. S., Alter, B. P., Ebell, W. (2008). “Cancer risks in Fanconi anemia: Findings from the German Fanconi Anemia Registry”. Haematologica, 93(4), 511–517. https://doi.org/10.3324/haematol.12234